Dr. Neeraj Agarwal's team at Huntsman Cancer Institute in Salt Lake City has found that pairing two drugs can cut the risk of prostate cancer progression nearly in half for patients whose tumors carry specific genetic mutations. The TALAPRO-3 trial—a Phase III clinical study published in the New England Journal of Medicine—offers a concrete path forward for men facing one of the disease's toughest challenges: the moment when cancer stops responding to hormone therapy.
Prostate cancer, like many cancers, feeds on biology. In this case, male sex hormones called androgens fuel tumor growth. For patients with metastatic castration-sensitive prostate cancer—disease that has spread beyond the prostate but still responds to hormone-lowering treatments—doctors can deploy androgen deprivation therapy, essentially medical castration through drugs or surgery. But inevitably, some cancers evolve resistance. When tumors stop slowing in response to dropping testosterone levels, they become castration resistant, and treatment options narrow sharply. This transition represents a critical turning point in patient outcomes.
Agarwal's trial tackled this problem head-on by testing whether combining two precision drugs could extend the window before resistance develops. The study enrolled patients with genetic mutations—particularly BRCA1 and BRCA2 alterations, which signal more aggressive disease—and randomized them to receive either enzalutamide alone, the current standard of care, or enzalutamide plus talazoparib. Enzalutamide (brand name XTANDI) blocks the androgen receptor, preventing male hormones from feeding cancer cells. Talazoparib (TALZENNA) is a PARP inhibitor that prevents damaged cancer cells from repairing themselves. The combination works on two fronts simultaneously.
The results were striking. Among patients receiving both drugs, radiographic progression-free survival at three years reached 77 percent—meaning the cancer remained stable on imaging scans. For those on enzalutamide alone, that figure was 56 percent. That 21-percentage-point gap translates to a 52 percent reduction in the risk of disease progression or death. The benefit extended across the broader patient population regardless of specific mutation type. Since BRCA and other gene alterations appear in roughly 25 to 30 percent of patients with this form of advanced prostate cancer, the implications reach thousands of men annually.
Agarwal emphasizes a point that transforms these numbers into clinical practice: "Delaying progression to castration-resistant disease, when hormone therapy will no longer work, remains a significant challenge in patients with an earlier stage of metastatic prostate cancer, especially true for patients with mutations including BRCA1 and BRCA2, who often experience poorer outcomes." With more than three years of follow-up data, the combination showed durable disease control without meaningful deterioration in most patient-reported quality-of-life measures.
The findings underscore a broader shift in cancer care toward genetic precision. Agarwal stresses the importance of routine genetic testing as part of initial prostate cancer evaluation. Once mutations are identified, patients can begin the combination therapy earlier and potentially slow progression substantially. This personalizes treatment at a critical diagnostic moment, moving beyond one-size-fits-all hormone therapy toward interventions matched to biology. For men with gene-altered tumors, the path from diagnosis to resistance just became longer—and that matters profoundly.